Australia
Hydrexia and Pure Hydrogen Sign Commercial Agreement in Australia
SYDNEY and SHANGHAI, April 7, 2025 /PRNewswire/ -- Hydrexia Pty Ltd, a wholly-owned subsidiary of Hydrexia Holding Limited ("Hydrexia"), aleading hydrogen technology solution provider, and Pure Hydrogen ("PH") a leading hydrogen ecosystem developer inAustralia today announced that the two compani...
2025-04-07 21:00
2396
Bonnell Electric Unleashes the 775 Series: The Future of Electric Performance is Here
AUSTIN, Texas, April 1, 2025 /PRNewswire/ -- Bonnell Electric is shaking up the e-MTB and e-moto landscape with the official launch of the 775 series. A revolutionary blend of power, precision, and adaptability, the 775 lineup is designed to push boundaries, offering three distinct ways to ride—w...
2025-04-01 23:30
3309
Seeing Machines Announces 3D Camera Technology for Next-Generation In-Cabin Monitoring Systems
* Seeing Machines and Airy3D partner to supply the Automotive industry with low-impact, trustworthy 3D-vision for future in-cabin systems. CANBERRA, Australia, April 1, 2025 /PRNewswire/ -- Seeing Machines, the advanced computer vision technology company that designs AI-powered operator monitor...
2025-04-01 22:20
2414
Canadian Solar and Flow Power to Install Innovative Anti-Hail Solar Panels
Canadian Solar's new anti-hail technology is set to be installed at a new South
Australian solar BESS energy project by Flow Power, enhancing the resilience of
solar energy inAustralia's harsh climate.
KITCHENER, ON, April 1, 2025 /PRNewswire/ -- Canadian Solar Inc.
2025-04-01 19:00
2483
ECHO IQ SIGNS STRATEGIC PARTNERSHIP AND INTEGRATION AGREEMENTS WITH SCIMAGE AND MEDAXIOM TO EXPAND ECHOSOLV AS ACROSS 36 US CARDIOLOGY NETWORKS
* EchoSolv AS will be fully integrated into ScImage's medical workflow platform, facilitating streamlined deployment within MedAxiom's hospital and cardiology networks. * ScImage is a nationally recognised Cloud and integrated workflow management platform, with over 1,200 users, specialisin...
2025-04-01 13:39
2536
NEURIM PHARMACEUTICALS RECEIVES EUROPEAN MARKETING AUTHORIZATION FOR PEDIATRIC PROLONGED-RELEASE MELATONIN (SLENYTO®) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
TEL AVIV, Israel, March 26, 2025 /PRNewswire/ -- Neurim Pharmaceuticals
2025-03-26 17:00
3090
Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data Presented at EAU 2025
NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the presentation of positive preliminary data from its ongoing Phase I clinical trial of ...
2025-03-24 20:30
1660
Seeing Machines announces new technology and safety appointments
CANBERRA, Australia, March 24, 2025 /PRNewswire/ -- Seeing Machines Limited (AIM: SEE, "Seeing Machines" or the "Company"), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, is pleased to announce the appointment ofJoh...
2025-03-24 15:00
1915
GCF Global Research Amplifies Movie-Goers' Voices: They Want More
Nothing Stands in the Way of a Cinema Visit When the Right Movie is Playing SYDNEY, March 19, 2025 /PRNewswire/ -- The Global Cinema Federation (GCF), representing global cinema exhibition, is excited to announce the results of its latest global customer research, highlighting the voices of consu...
2025-03-20 02:00
1850
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL
* Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. * CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid tumor...
2025-03-06 08:10
2222
SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.
HIGHLIGHTS * Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase (Phase II stage) of the SECuRE study. * Based on the efficacy and safety assessment of all cohorts and the focus on earlier stages of treatment, the SRC...
2025-03-05 21:44
2621
Seeing Machines names Mitsubishi Electric Automotive America as a referral partner to drive accelerated sales of Guardian Generation 3 in The Americas
CANBERRA, Australia, Feb. 24, 2025 /PRNewswire/ -- Seeing Machines Limited (AIM: SEE), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, announces that Mitsubishi Electric Automotive America, Inc. ("MEAA") has signed a...
2025-02-24 20:00
2491
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
* YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 * First-in-class novel PTH replacement therapy * Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH s...
2025-02-21 00:01
2723
Silicon Quantum Computing achieves world-leading accuracy of Grover's algorithm without error correction
SYDNEY, Feb. 20, 2025 /PRNewswire/ -- Silicon Quantum Computing (SQC), a pioneer in quantum computing and atomic manufacturing, today announced that it has demonstrated world-leading accuracy in the operation of Grover's algorithm without error correction, i.e. in its native pure form. This prove...
2025-02-20 18:10
2384
Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
SYDNEY, Feb. 19, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce thatthe Un...
2025-02-19 22:09
2696
ClassDojo CTO backs kid-tech gaming app, Polymath in $1M raise
AUCKLAND, New Zealand, Feb. 17, 2025 /PRNewswire/ -- Kid-tech startup Polymath has secured$1M USD in funding with notable investment from ClassDojo CTO Liam Don in their first angel round, followed by a venture-backed pre-seed raise co-led by Blackbird Ventures and GD1. This investment accelerate...
2025-02-18 02:30
2401
An independent third-party performance assessment confirms that the Aquarius AQ 150 engine demonstrates 25% higher efficiency than the world's leading engines, operates on multiple fuel types, and is significantly lighter than existing alternatives
As a reminder, Aquarius' innovative systems generate and supply clean electricity, designed to enable ultra-fast charging for electric vehicles in the rapidly growing EV market. Aquarius' systems are smaller and more efficient than existing market solutions and do not depend on the power grid. A...
2025-02-14 06:00
6750
Nuix Awarded Patent for Breakthrough Deep Learning Technology for Training AI
SYDNEY, Feb. 10, 2025 /PRNewswire/ -- Nuix Ltd. (ASX: NXL), a global leader in data processing, investigative analytics and intelligent software, has today announced it has been granted a patent for pioneering a novel technology system that uses advanced deep learning techniques to better train a...
2025-02-11 11:35
1987
Canadian Solar's e-STORAGE to Deliver 960 MWh of Energy Storage Systems for Copenhagen Infrastructure Partners in Australia
KITCHENER, ON, Feb. 10, 2025 /PRNewswire/ -- Canadian Solar Inc
2025-02-10 20:00
3217
Argent BioPharma: A Hidden Gem traded Under $12M--Edison Group Report Assigned a $327M Valuation to Its Breakthrough Epilepsy Treatment
PERTH, Australia, Feb. 6, 2025 /PRNewswire/ -- Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company brings hope to epilepsy patients. For thousands of patients with refractory epilepsy—commonly referred to as drug-resistant epilepsy—the search for effective trea...
2025-02-06 05:00
2472
Week's Top Stories
Most Reposted
SGTraDex and IMDA Receive Pro-Enterprise Impact & Partnership Award for Interoperable Digital Documents Against Payment Trade Cooperation
[Picked up by 314 media titles]
2025-11-25 15:37
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 312 media titles]
2025-11-27 07:25SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 292 media titles]
2025-11-29 09:00
HOTEL GROOVE SHINJUKU strengthens its services for deaf and hard of hearing guests
[Picked up by 289 media titles]
2025-11-25 10:00
Pop the 90s: The Westin Surabaya and Four Points Pakuwon Indah Welcomes 2026 with a Spectacular Live Show Featuring Project Pop
[Picked up by 286 media titles]
2025-11-26 10:49
Most Read
LightInTheBox to Hold 2025 Annual General Meeting on December 19, 2025
2025-11-25 21:20
2765
MINISO Unveils Australia's First and Largest MINISO LAND Flagship at Sydney Chatswood
2025-11-27 18:56
2310
